Janssen Submits Supplemental New Drug Application to U.S. FDA for OLYSIOâ¢ (Simeprevir) for Once-Daily Use in Combination with Sofosbuvir for 12 Weeks for the Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C